Weight Loss Pill 'Wegovy' Launches in Israel, Intensifying Market Competition
Translated & summarized from Ice by baba
Novo Nordisk's popular weight loss drug Wegovy is launching in Israel as an oral tablet this Wednesday, offering an alternative to weekly injections. Clinical trials show the tablets lead to an average 16.6% weight loss after a year, though injectables are more effective. The pill's convenience is expected to significantly impact the multi-billion dollar GLP-1 market, intensifying competition with Eli Lilly's Mounjaro. Monthly costs will range from 600 to 1,300 shekels, with side effects similar to other GLP-1 drugs.
The story in 5 lines · by baba
- Wegovy weight loss tablets are launching in Israeli pharmacies on Wednesday.
- The oral form offers an alternative to weekly injections for hundreds of thousands of Israelis.
- Tablets show 16.6% average weight loss after a year, compared to 20-25% for injectables.
- Monthly treatment costs for Wegovy tablets will range from 600 to 1,300 shekels.
- The launch intensifies competition in the global GLP-1 drug market.
The oral tablet version of the popular weight loss drug Wegovy, manufactured by Novo Nordisk, will be available in Israeli pharmacies starting Wednesday. This launch is a significant development for hundreds of thousands of Israelis struggling with excess weight, particularly those who were hesitant to use the weekly injections.
The introduction of the pill marks the next phase in the global battle for the GLP-1 drug market, a sector valued at tens of billions of dollars. Clinical data indicates that daily intake of Wegovy tablets leads to an average weight loss of approximately 16.6% after a year of continuous treatment. This offers a distinct advantage over its direct competitor, 'Pounda', which arrived in Israel about six weeks ago and shows a more moderate average weight reduction.
However, when comparing the oral tablets to existing injectable medications, a difference in efficacy is noted. Leading injections, including Wegovy injections and Eli Lilly's Mounjaro, can achieve impressive weight loss rates of 20% to 25%. Experts, though, anticipate that the convenience of taking a pill, along with the absence of refrigeration and repeated injections, will shift market demand. Projections suggest that within a few years, pills will constitute the majority of the weight loss drug market.
The arrival of the tablets intensifies the fierce competition between international pharmaceutical companies. Novo Nordisk, a pioneer with Ozempic and Wegovy, aims to solidify its leading position against American rival Eli Lilly, which has shown strong performance with tirzepatide (Mounjaro/Zepbound). The development of the tablets is intended not only to improve patient adherence but also to address severe production bottlenecks in injectable pens, which have caused significant shortages globally and in Israel.
The monthly cost for Wegovy tablets is expected to range between 600 and 1,300 shekels, depending on the required dosage. Regarding safety and side effects, the profile of the tablets is similar to other GLP-1 medications, including potential nausea and abdominal pain, which are typically temporary for most users. It remains to be seen if the convenience of the pill will win over Israelis and alter the dynamics of the local weight loss market.
Mentioned
